161 related articles for article (PubMed ID: 37956832)
1. Safety assessment of Brexpiprazole: Real-world adverse event analysis from the FAERS database.
Jiang Y; Zhou L; Shen Y; Zhou Q; Ji Y; Zhu H
J Affect Disord; 2024 Feb; 346():223-229. PubMed ID: 37956832
[TBL] [Abstract][Full Text] [Related]
2. Signal mining and analysis for central nervous system adverse events due to taking oxycodone based on FAERS database.
Wu X; Zhang L; Huang H; Huang L; Lu X; Wang Z; Xiao J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Mar; 48(3):422-434. PubMed ID: 37164926
[TBL] [Abstract][Full Text] [Related]
3. Unveiling potential adverse events associated with escitalopram oxalate: A real-world analysis based FDA adverse event reporting system database.
Jiang Y; Cheng Y; Du Z; Shen Y; Zhou Q; Ji Y; Zhu H
J Psychopharmacol; 2024 Jun; 38(6):567-578. PubMed ID: 38678377
[TBL] [Abstract][Full Text] [Related]
4. Analysis of post-market adverse events of istradefylline: a real-world study base on FAERS database.
Jiang Y; Lu R; Zhou Q; Shen Y; Zhu H
Sci Rep; 2024 Apr; 14(1):7659. PubMed ID: 38561511
[TBL] [Abstract][Full Text] [Related]
5. Safety evaluation of ceftazidime/avibactam based on FAERS database.
Zhang X; Jiang Y; Guo Y; Zhou W; Qiao W; Zhu H; Qi Z
Infection; 2024 Jun; ():. PubMed ID: 38842750
[TBL] [Abstract][Full Text] [Related]
6. Commonality of drug-associated adverse events detected by 4 commonly used data mining algorithms.
Sakaeda T; Kadoyama K; Minami K; Okuno Y
Int J Med Sci; 2014; 11(5):461-5. PubMed ID: 24688309
[TBL] [Abstract][Full Text] [Related]
7. A real-world data analysis of topotecan in the FDA Adverse Event Reporting System (FAERS) database.
Yang H; Wan Z; Chen M; Zhang X; Cui W; Zhao B
Expert Opin Drug Metab Toxicol; 2023 Apr; 19(4):217-223. PubMed ID: 37243615
[TBL] [Abstract][Full Text] [Related]
8. Adverse Events of Oral GLP-1 Receptor Agonist (Semaglutide Tablets): A Real-World Study Based on FAERS from 2019 to 2023.
Xiong S; Gou R; Liang X; Wu H; Qin S; Li B; Luo C; Chen J
Diabetes Ther; 2024 May; ():. PubMed ID: 38776037
[TBL] [Abstract][Full Text] [Related]
9. Analysis of the nervous system and gastrointestinal adverse events associated with solifenacin in older adults using the US FDA adverse event reporting system.
Nicholls C; Chyou TY; Nishtala PS
Int J Risk Saf Med; 2023; 34(1):63-73. PubMed ID: 35491805
[TBL] [Abstract][Full Text] [Related]
10. Pharmacovigilance Study of Infigratinib: A Safety Analysis of the FDA Adverse Event Reporting System.
Zhao D; Long X; Zhou J; Wang J
Drugs R D; 2023 Dec; 23(4):403-409. PubMed ID: 37700091
[TBL] [Abstract][Full Text] [Related]
11. Data mining for adverse drug reaction signals of daptomycin based on real-world data: a disproportionality analysis of the US Food and Drug Administration adverse event reporting system.
Chen JJ; Huo XC; Wang SX; Wang F; Zhao Q
Int J Clin Pharm; 2022 Dec; 44(6):1351-1360. PubMed ID: 36178607
[TBL] [Abstract][Full Text] [Related]
12. Adverse drug events associated with linezolid administration: a real-world pharmacovigilance study from 2004 to 2023 using the FAERS database.
Zou F; Cui Z; Lou S; Ou Y; Zhu C; Shu C; Chen J; Zhao R; Wu Z; Wang L; Chen Z; Chen H; Lan Y
Front Pharmacol; 2024; 15():1338902. PubMed ID: 38434706
[No Abstract] [Full Text] [Related]
13. Comparing adverse events of tenecteplase and alteplase: a real-world analysis of the FDA adverse event reporting system (FAERS).
Shi FE; Yu Z; Sun C; Gao P; Zhang H; Zhu J
Expert Opin Drug Saf; 2024 Feb; 23(2):221-229. PubMed ID: 37554093
[TBL] [Abstract][Full Text] [Related]
14. Mining and analysis of adverse event signals of Cariprazine based on the real-world data of FAERS database.
Zhu H; Qu Y; Du Z; Zhou Q; Shen Y; Jiang Y; Zhou Z; Zhou H
J Affect Disord; 2024 Feb; 347():45-50. PubMed ID: 37992768
[TBL] [Abstract][Full Text] [Related]
15. Acute renal failure and cardiac arrhythmias associated with remdesivir use in patients with COVID-19 infections: Analysis using the US FDA adverse event reporting system.
Orogun L; Chyou TY; Nishtala PS
Int J Risk Saf Med; 2023; 34(2):87-99. PubMed ID: 37154187
[TBL] [Abstract][Full Text] [Related]
16. Postmarketing safety of anaplastic lymphoma kinase (ALK) inhibitors: an analysis of the FDA Adverse Event Reporting System (FAERS).
Omar NE; Fahmy Soliman AI; Eshra M; Saeed T; Hamad A; Abou-Ali A
ESMO Open; 2021 Dec; 6(6):100315. PubMed ID: 34864500
[TBL] [Abstract][Full Text] [Related]
17. A disproportionality analysis of FDA adverse event reporting system (FAERS) events for ticagrelor.
Pan Y; Wang Y; Zheng Y; Chen J; Li J
Front Pharmacol; 2024; 15():1251961. PubMed ID: 38655177
[TBL] [Abstract][Full Text] [Related]
18. Adverse reaction signals mining and hemorrhagic signals comparison of ticagrelor and clopidogrel: A pharmacovigilance study based on FAERS.
Tang S; Wu Z; Xu L; Wen Q; Zhang X
Front Pharmacol; 2022; 13():970066. PubMed ID: 36263117
[No Abstract] [Full Text] [Related]
19. A real-world disproportionality analysis of ospemifene: data mining of the public version of FDA adverse event reporting system.
Wen H; Lu C; Zhang M; Qi X
Expert Opin Drug Saf; 2023; 22(11):1133-1142. PubMed ID: 37578751
[TBL] [Abstract][Full Text] [Related]
20. Novel Adverse Events of Iloperidone: A Disproportionality Analysis in US Food and Drug Administration Adverse Event Reporting System (FAERS) Database.
Subeesh V; Maheswari E; Singh H; Beulah TE; Swaroop AM
Curr Drug Saf; 2019; 14(1):21-26. PubMed ID: 30362421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
